Clinical Research Directory
Browse clinical research sites, groups, and studies.
An Open Label Clinical Study to Evaluate Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (FORWARD Study)
Sponsor: Annexon, Inc.
Summary
The goal of this open label study is to measure pharmacokinetics, pharmacodynamics, early efficacy, and safety of tanruprubart in adult and pediatric participants, in the United States, Canada, and Europe.
Official title: An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)
Key Details
Gender
All
Age Range
12 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-09-12
Completion Date
2028-06-30
Last Updated
2026-05-28
Healthy Volunteers
No
Conditions
Interventions
Tanruprubart
Solution for IV infusion.
Locations (13)
St. Joseph's Hospital & Medical Center - Barrow Neurological Institute
Phoenix, Arizona, United States
HonorHealth Bob Bové Neuroscience Institute
Scottsdale, Arizona, United States
Profound Research LLC
Carlsbad, California, United States
Children's Hospital of Orange County
Orange, California, United States
University of California Irvine
Orange, California, United States
University of Colorado Hospital
Aurora, Colorado, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
Ochsner LSU Health
Shreveport, Louisiana, United States
University Massachusetts Chan Medical School
Worcester, Massachusetts, United States
Henry Ford Health
Detroit, Michigan, United States
Mayo Rochester
Rochester, Minnesota, United States
Aarhus University Hospital
Aarhus, Aarhus N, Denmark